Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $15.00 Consensus Target Price from Analysts

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has been given a consensus recommendation of “Hold” by the three research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $16.50.

A number of research analysts have recently weighed in on VYGR shares. Wall Street Zen raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Voyager Therapeutics in a report on Tuesday.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 14,197 shares of the firm’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $3.79, for a total value of $53,806.63. Following the completion of the sale, the chief executive officer directly owned 484,060 shares of the company’s stock, valued at $1,834,587.40. This trade represents a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders sold 49,783 shares of company stock valued at $188,694 over the last three months. Company insiders own 6.39% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

A number of large investors have recently made changes to their positions in the stock. Bank of Montreal Can bought a new stake in shares of Voyager Therapeutics during the 2nd quarter valued at $36,000. Wexford Capital LP bought a new position in Voyager Therapeutics in the 3rd quarter worth about $42,000. ProShare Advisors LLC purchased a new position in Voyager Therapeutics during the 4th quarter valued at about $44,000. CIBC Asset Management Inc purchased a new position in Voyager Therapeutics during the 4th quarter valued at about $45,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Voyager Therapeutics during the second quarter valued at about $50,000. 48.03% of the stock is owned by institutional investors.

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR opened at $3.76 on Thursday. The company’s 50-day moving average is $3.92 and its 200 day moving average is $4.19. The company has a market capitalization of $224.10 million, a P/E ratio of -1.85 and a beta of 1.32. Voyager Therapeutics has a fifty-two week low of $2.64 and a fifty-two week high of $5.55.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.08. The company had revenue of $13.46 million during the quarter, compared to analyst estimates of $10.49 million. Voyager Therapeutics had a negative net margin of 296.53% and a negative return on equity of 51.35%. As a group, research analysts predict that Voyager Therapeutics will post -0.91 earnings per share for the current year.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.